FOSTAMATINIB

FDA Drug Profile — TAVALISSE

FOSTAMATINIB is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including TAVALISSE. Available dosage form: tablet.

Drug Details

Generic Name
FOSTAMATINIB
Brand Names
TAVALISSE
Application Number
NDA209299
Sponsor
Rigel Pharmaceuticals, Inc.
NDC Codes
2
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
FOSTAMATINIB

Indications and Usage

1 INDICATIONS AND USAGE TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.